Courtesy of Benzinga.
GlaxoSmithKline (NYSE: GSK) is reportedly in discussions this weekend with Human Genome Sciences (NASDAQ: HGSI) to increase its previous offer, according to Reuters.
Human Genome had previously rejected GSK’s $13/share bid. There was heavy volume in the October 16 HGSI call on Friday just before the close. HGSI closed at $13.58 on Friday.